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A B S T R A C T
Background
People with advanced ovarian or gastrointestinal cancer may develop malignant bowel obstruction (MBO). They are able to tolerate
limited, if any, oral or enteral (via a tube directly into the gut) nutrition. Parenteral nutrition (PN) is the provision of macronutrients,
micronutrients, electrolytes and fluid infused as an intravenous solution and provides a method for these people to receive nutrients.
There are clinical and ethical arguments for and against the administration of PN to people receiving palliative care.
Objectives
To assess the effectiveness of home parenteral nutrition (HPN) in improving survival and quality of life in people with inoperable
MBO.
Search methods
We searched the following electronic databases: Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 1),MEDLINE
( Ovid), Embase ( Ovid), BNI, CINAHL, Web of Science and NHS Economic Evaluation and Health Technology Assessment up
to January 2018, ClinicalTrials.gov ( http://clinicaltrials.gov/) and in the World Health Organization ( WHO) International Clinical
Trials Registry Platform ( ICTRP) search portal ( http://apps.who.int/trialsearch/). In addition, we handsearched included studies and
used the ‘Similar articles’ feature on PubMed for included articles.
Selection criteria
We included any studies with more than five participants investigating HPN in people over 16 years of age with inoperable MBO.
Data collection and analysis
We extracted the data and assessed risk of bias for each study. We entered data into Review Manager 5 and used GRADEpro to assess
the quality of the evidence.
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Main results
We included 13 studies with a total of 721 participants in the review. The studies were observational, 12 studies had only one relevant
treatment arm and no control and for the one study with a control arm, very few details were given. The risk of bias was high and
the certainty of evidence was graded as very low for all outcomes. Due to heterogeneity of data, meta-analysis was not performed and
therefore the data were synthesised via a narrative summary.
The evidence for benefit derived from PN was very low for survival and quality of life. All the studies measured overall survival and
636 (88%) of participants were deceased at the end of the study. However there were varying definitions of overall survival that yielded
median survival intervals between 15 to 155 days (range three to 1278 days). Three studies used validated measures of quality of life.
The results from assessment of quality of life were equivocal; one study reported improvements up until three months and two studies
reported approximately similar numbers of participants with improvements and deterioration. Different quality of life scales were used
in each of the studies and quality of life was measured at different time points. Due to the very low certainty of the evidence, we are very
uncertain about the adverse events related to PN use. Adverse events were measured by nine studies and data for individual participants
could be extracted from eight studies. This revealed that 32 of 260 (12%) patients developed a central venous catheter infection or
were hospitalised because of complications related to PN.
Authors’ conclusions
We are very uncertain whether HPN improves survival or quality of life in people with MBO as the certainty of evidence was very low
for both outcomes. As the evidence base is limited and at high risk of bias, further higher-quality prospective studies are required.
P L A I N L A N G U A G E S U M M A R Y
Home parenteral nutrition for people with bowel obstruction caused by cancer
What is the issue?
People with advanced cancer within the abdominal cavity can develop blockages of the bowel that cannot be treated surgically. This
may cause nausea and vomiting and an inability to absorb enough nutrition via the gut. An alternative to conventional feeding when
the gut does not work, is feeding through a vein, known as parenteral nutrition (PN). This is often used in hospital to support patients
when return of gut function is expected. However, it can also be considered as part of palliative treatment in advanced cancer when
return of gut function is unlikely.
Why is it important?
PN in people with blockage of the bowel due to advanced, inoperable cancer is controversial. Treatments are largely limited to best
supportive care and there are arguments for and against artificial feeding in this situation. There is some evidence that it may lengthen
survival, but the treatment can be burdensome and risky for individuals where quality of life is a priority.
We asked:
Is PN effective in improving survival and quality of life in people with inoperable blockage of the bowel caused by advanced cancer?
We found:
The benefits of PN are uncertain as the evidence is of very low certainty, provided mainly by studies that only looked at people who
received PN rather than comparing patients who received PN with those who did not. As we found no randomised controlled trials,
we have included the results from 13 observational studies with a total of 721 participants. For 12 of the studies, there was only one
relevant treatment group and no control group. Therefore, the results are only for people receiving PN and we have no information
about those not receiving it. The average survival time for people on PN varied from three to 1278 days. Only three studies measured
quality of life using a recognised measure. One study found quality of life improved and two studies found similar numbers of people
both improved and deteriorated. However, the three studies monitored quality of life at different points in time and measured it in
different ways. Side effects occurred in 12% of people in the eight studies that measured them.
This means:
Further research is needed to find out if PN is of benefit to people with an inoperable blockage of the bowel caused by advanced cancer.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Home parenteral nutrition for people with inoperable bowel cancer
Patient or population: people with advanced cancer with inoperable malignant bowel obstruct ion (MBO)
Setting: outpat ient/ home care
Intervention: parenteral nutrit ion (PN)
Outcomes Impact of participants
(studies)
Certainty of the evidence
(GRADE)
Length of Survival We are uncertain whether PN improves
survival for pat ients with MBO receiving
PN. It was not possible to combine data
due to heterogeneity of cancer diagnosis
and dif fering start ing points for measuring
survival.There was a wide variat ion of sur-
vival lengths reported in the studies, with
median survival periods of 15 to 155 days
(range 3 to 1278 days) and mean survival
intervals of 85 to 164 days (range 8 to
1004 days)
721
(13 observat ional studies)
⊕©©©
Very Low 12
Quality of lif e We are very uncertain if PN proves qual-
ity of lif e for pat ients with MBO receiving
PN. Three studies used validated ques-
t ionnaires. One of these studies found an
improvement over three months for global
quality of lif e. Two studies had a mixed
picture; one measuring well-being at one
month and one overall quality of lif e at
two months. Around half of part icipants
showed no change, a quarter to a f if th de-
teriorated and a quarter to a third improved
188
(3 observat ional studies)
⊕©©©
Very Low 12
3
H
o
m
e
p
a
re
n
te
ra
l
n
u
tritio
n
fo
r
p
e
o
p
le
w
ith
in
o
p
e
ra
b
le
m
a
lig
n
a
n
t
b
o
w
e
l
o
b
stru
c
tio
n
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
8
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Adverse events We are very uncertain about the impact of
PN on adverse events of pat ients in MBO
as the quality of the evidence was very low.
There is lim ited evidence about adverse
events. Although nine studies reported this
outcome, data for individual pat ients could
be extracted f rom eight studies and 32/ 260
(12%) pat ients developed a central venous
catheter infect ion or were hospitalised for
PN complicat ions
280
(9 observat ional studies)
⊕©©©
Very Low 12
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 The studies were down graded by three points as all of the studies were observat ional so pat ients were not allocated
treatments at random and healthcare professionals and pat ients were not blinded to treatment received. Therefore, the
studies are at very high risk of bias.
2 Narrat ive synthesis conducted est imates not precise
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B A C K G R O U N D
Description of the condition
Malignant bowel obstruction (MBO) is caused by mechanical,
vascular or neurological dysfunction of the small or large bowel
(Anthony 2007; Ripamonti 2008). People with MBO experience
symptoms such as nausea, vomiting, abdominal distention and
pain (Mercadante 1995).
MBO occurs most often in people who have ovarian and gastroin-
testinal cancers. There is a wide variation in quoted incidence rates
of MBO as data have been drawn from small retrospective and
autopsy studies, with reported rates varying between 5% and 51%
in women with ovarian cancer and 10% to 28% in people with
gastrointestinal cancer (Cousins 2016). Other cancers that have
been associated with MBO include bladder cancer (3% to 10%)
and endometrial (womb) cancer (3% to 11%), as well asmetastatic
breast cancer and melanoma (Ferguson 2015).
Some people with MBO have disease that is amenable to surgi-
cal treatment on first presentation (Cousins 2016; Daniele 2015).
However, people who experience recurrences ofMBO are unlikely
to benefit from further surgery, at which point they are deemed
to have inoperable MBO (DeBernardo 2009; Mercadante 2007).
Rates of survival in the literature for people with MBO range from
less than a month to up to 12 months; this wide range is due to
differences in patient selection and whether the MBO resolves,
treatments and definitions of survival (Mercadante 1995; Porzio
2011). However, some studies have quoted an average survival of
between two and three months (Hardy 1998; Laval 2000). Peo-
ple with inoperable MBO are managed medically using corticos-
teroids, antiemetics and antisecretory agents (Ferguson 2015). For
people with uncontrolled vomiting, a naso-gastric tube or venting
gastrostomy may be considered (Brett 1986). People with inoper-
able MBO are unable to maintain adequate oral intake and may
benefit from parenteral nutrition (PN).
Description of the intervention
PN is the provision ofmacronutrients, micronutrients, electrolytes
and fluid infused as an intravenous solution. Individuals are as-
sessed for their energy, nutrient and fluid requirements and PN
solutions are then tailored to these requirements (Bielawska 2017).
This solution is usually administrated to a patient during the night,
over 10 to 15 hours, depending on individual tolerance, nutri-
tion and fluid requirements (Wanten 2011). Short-term PN may
be initially administrated via a peripheral or central vein. How-
ever, patients receive long-term PN and home parenteral nutrition
(HPN) via a central venous catheter (Lai 2016; Pittiruti 2009).
This Cochrane Review will focus on such nutritional support.
How the intervention might work
In PN, nutrients and fluids are delivered to patients via the venous
route. People with MBO are able to tolerate limited, if any, oral
or enteral nutrition (delivery of nutrients into the gastrointestinal
tract by means of a tube), and thus are unable to meet their nu-
tritional requirements orally. PN therefore provides a method for
these patients to receive nutrients and fluid that otherwise would
be inaccessible to them. PN may improve survival (Brard 2006).
Median survival in people with MBO who receive PN is around
80 days (Abu-Rustum 1997; Naghibi 2015). The treatment may
also improve quality of life and there have been reports of symp-
tomatic improvement after starting PN (Mercadante 1995).
Why it is important to do this review
The provision of PN in patients undergoing palliative care is
somewhat controversial. There is a fundamental human right to
food, which has been recognised by the United Nations (UN)
(UN 1948). However, there are clinical and ethical arguments
for and against the administration of PN, related to what the
person wants, their symptoms and clinical evidence. There is
some evidence of benefit in terms of survival, but the treatment
is costly to the healthcare provider and may be burdensome for
patients (Abu-Rustum 1997; Brard 2006; DiBaise 2007; Hoda
2005; Naghibi 2015; Pasanisi 2001). There is a lack of consen-
sus on the role of PN in this patient group which is reflected
in varying rates worldwide of people with active cancer receiving
PN (Howard 1995; Smith 2016). In the USA, people with can-
cer were the largest proportion (42%) of people receiving HPN
from 1985 to 1992, although current data show that people with
short-bowel syndrome are now the largest group receiving HPN
(Howard 2006;Winkler 2016). In Europe as a whole, cancer is the
primary indication for HPN in 39% of cases, although there are
variations in different European countries for example, Denmark
8%, Belgium 23%, Spain, 39% and theNetherlands 60% (Bakker
1999). In the UK, this figure is 27% of patients (Smith 2016); all
centres providing HPN to patients, including those with cancer,
are expected to comply with the British Intestinal Failure Alliance
Position statement (British Intestinal Failure Alliance 2016) . This
Cochrane Review examines the potential benefits and disadvan-
tages of PN for people with cancer focusing on benefits, including
survival, quality of life or both, and disadvantages including any
adverse events that result from the treatment.
O B J E C T I V E S
To assess the effectiveness of home parenteral nutrition (HPN) in
improving survival and quality of life in people with inoperable
MBO.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
Quantitative
We did not envisage identification of randomised controlled tri-
als (RCTs) due to sparse data and therefore we included non-
randomised studies,quasi-RCTs, non-randomised controlled tri-
als, prospective and retrospective cohort studies, including single-
arm studies and case series of more than five participants.
We excluded case series with less than five participants.
Qualitative
We planned to include any qualitative studies (phenomenological,
ethnographic or grounded theory) that used recognised methods
of qualitative data collection (interview, observation, focus group)
and analysis.
Types of participants
Inclusion criteria
The participants fulfilled each of the following criteria.
• People over 16 years of age with inoperable MBO.
• Receiving PN via a central venous catheter.
• Receiving or planned to receive PN at home.
• No curative treatment: we deemed any chemotherapy or
radiotherapy in this setting as palliative.
Exclusion criteria
• Bowel obstruction caused by pseudomyxoma peritonei and
desmoid tumours as these tumours are slow growing and
individuals have more favourable survival.
• Receiving PN through a peripheral vein.
• Receiving only intravenous fluids that lack protein and
calories.
• Studies with < 70% participants receiving PN for inoperable
MBO, unless we could extract data on MBO participants.
If it was unclear whether the participants met the inclusion criteria
based on the published data, we contacted the study authors for
further information. If we were still unable to establish if the study
met the criteria, the study was excluded.
Types of interventions
Intervention
• Treatment with PN delivered through a central venous
catheter.
Control
• No PN support.
• Other nutritional interventions, such as elemental diet or
intravenous fluids alone.
Types of outcome measures
Primary outcomes
• Length of survival from diagnosis of MBO or, if not given,
implementation of PN until death from any cause.
• Quality of life: any measure of quality of life completed by
participants, carers or an independent rater. However, we gave
preference to validated questionnaires, e.g. the European
Organisation for Research and Treatment of Cancer Quality of
Life Questionnaire (EORTC QLQ-C30).
Secondary outcomes
• Measurement of gastrointestinal symptoms e.g. nausea,
vomiting, abdominal distention, diarrhoea, pain on eating using
a validated questionnaire, or recorded in a dichotomous form i.e.
present/absent.
• Any measure of nutritional status, such as anthropometry
or validated measures e.g. subjective global assessment.
• Qualitative reports of quality of life or symptoms.
• Where multiple time points were recorded, we gave priority
to baseline, one month, three months and six months
observations.
• Adverse events: sepsis caused by central venous catheter
infection/hospitalisation due to HPN complications (other
catheter complications, fluid overload including peripheral
oedema or ascites), were reported as present or absent.
• Adverse events if they occurred at any time point during the
administration of PN.
• Health economic outcomes: cost of treatment, any
measurement of cost-effectiveness of treatment such as quality
adjusted life year.
Search methods for identification of studies
Electronic searches
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We identified relevant studies by conducting searches (January
2018) of the following electronic databases.
• Cochrane Central Register of Controlled Trials
(CENTRAL, 2018, Issue 1)
• Ovid MEDLINE (1946 to January 2018)
• Embase (1980 to January 2018)
We also searchedBristish Nursing Index (BNI), Cumulative Index
to Nursing and Allied Health Literature (CINAHL), Web of Sci-
ence and NHS Economic Evaluation Database (NHS EED) and
Health Technology Assessment (HTA) in January 2018. We con-
ducted a generic search for malignant bowel obstruction (MBO)
and parenteral nutrition (PN) which would include qualitative
and quantitative studies.
We searched for any currently recruiting trials in ClinicalTrials.gov
( http://clinicaltrials.gov/) and in the World Health Organization
(WHO) International Clinical Trials Registry Platform ( ICTRP)
search portal ( http://apps.who.int/trialsearch/).We contacted the
authors of any trials found which should have completed but for
which the results were not published.
The detailed search strategy for MEDLINE is in Appendix 1,
Embase in Appendix 2 and CENTRAL in Appendix 3.
Searching other resources
Wehandsearched selected articles to identify any other relevant ar-
ticles.We also found all included articles on PubMed and searched
for other pertinent articles using the ‘Similar articles’ feature.
Data collection and analysis
We followed the guidance of the Cochrane Handbook for System-
atic Reviews of Interventions (Higgins 2011). We entered data into
Review Manager (RevMan 2014). Although we planned to use
SPSS (version 23) (IBM corp 2015), statistical analysis was not
feasible in view of the data set.
Selection of studies
We downloaded all titles and abstracts retrieved by electronic
searching toEndNote and removedduplicates. Two review authors
(AMS, JS, AC, SL or CT) independently examined the remaining
references and excluded those studies that clearly did not meet the
inclusion criteria. JS obtained copies of the full-text of potentially
relevant references. Independently, two review authors (AMS and
JS) assessed the eligibility of the retrieved reports/publications. We
resolved any disagreement through discussion. If it was unclear
whether a study met the inclusion criteria, it was discussed with
a third review author (SB). We identified and excluded duplicate
reports and collatedmultiple reports of the same study so that each
study rather than each report was the unit of interest in the review.
We recorded the selection process in sufficient detail to complete
a PRISMA flow diagram and a Characteristics of included studies
table (Liberati 2009).
Data extraction and management
Two review authors (AMS, JS or LH) independently extracted
study characteristics andoutcomedata from included studies using
a piloted data collection form. We noted in the Characteristics
of included studies table if outcome data were not reported in
a usable way. We resolved disagreements by consensus and did
not need to involve a third review author (SB). One author (JS)
transferred data to the RevMan 5 file (RevMan 2014).We double-
checked that data had been entered correctly by comparing the
data presented in the systematic review with the study reports.
A second review author (AMS) did a ’spot-check’ to assess the
accuracy of the study characteristics against the study report.
For included studies, we extracted the following data.
• Author, year of publication and journal citation (including
language).
• Country.
• Setting.
• Inclusion and exclusion criteria.
• Study design, methodology.
• Source of funding.
• Study population:
◦ total number enrolled;
◦ age;
◦ co-morbidities;
◦ performance status at diagnosis of MBO;
◦ cancer diagnosis including, if indicated, staging,
number and sites of metastasis and treatments received;
◦ any data on confounding factors which might improve
a patient’s symptoms of MBO such as administration of steroids,
antisecretory medication or prokinetics.
• Intervention details:
◦ any details of nutrition received: PN nutritional
content, number of times given in a week and whether any other
oral intake was recorded;
◦ Primary outcomes and Secondary outcomes as
detailed above.
• Comparison:
◦ whether any oral intake was recorded or intravenous
fluids administered;
◦ Primary outcomes and Secondary outcomes as
detailed above.
• Risk of bias in study (see Assessment of risk of bias in
included studies section below).
• Duration of follow-up.
• We noted the time points at which outcomes were collected
and reported.
We planned to extract results as follows.
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• For time-to-event data (e.g. survival), we planned to extract
the log of the hazard ratio [log(HR)] and its standard error (SE)
from study reports. If these were not reported, we planned to
estimate the log (HR) and its SE using the methods of Parmar
1998.
• For dichotomous outcomes (e.g. gastrointestinal
symptoms) we planned to extract the number of participants in
each treatment arm who experienced the outcome of interest and
the number of participants assessed at the endpoint, in order to
estimate a risk ratio (RR).
• For continuous outcomes (e.g. quality of life measures), we
planned to extract the final value and standard deviation (SD) of
the outcome of interest and the number of participants assessed
at endpoint in each treatment arm at the end of follow-up, in
order to estimate the mean difference (MD) between treatment
arms and its SE.
However, it was not possible to conduct any of these analyses as
most studies only had a treatment group and no control, and for
the one study with a comparator insufficient details were given.
Assessment of risk of bias in included studies
We assessed and reported on the methodological risk of bias of
included studies in accordance with the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011), which recom-
mends the explicit reporting of the following individual elements.
• Selection bias: random sequence generation and allocation
concealment.
• Performance bias: blinding of participants and personnel.
• Detection bias: blinding of outcome assessment.
• Attrition bias: incomplete outcome data, which is less than
80% reported for primary outcomes.
• Reporting bias: selective reporting of outcomes.
• Other: any other risk of bias.
We assessed the risk of bias in non-randomised controlled studies
in accordance with the additional criteria below.
• Details of criteria for assignment of participants to
treatments:
◦ low risk of bias: yes;
◦ high risk of bias: no;
◦ unclear risk of bias: if no details provided.
• Comparability of treatment groups: no differences between
the two groups or differences controlled for, in particular with
reference to age, performance status at diagnosis of MBO, cancer
diagnosis, stage, grade, metastasis:
◦ low risk of bias: if at least two of these characteristics
were reported and any reported differences were controlled for;
◦ high risk of bias: if the two groups differed and
differences were not controlled for;
◦ unclear risk of bias: if fewer than two of these
characteristics were reported even if there were no other
differences between the groups, and other characteristics had
been controlled for.
Wedefined the following endpoint as a subjective outcome: quality
of life.
Wedefined the following endpoints as objective outcomes: survival
and adverse events (hospitalisation due to PN)..
Measures of treatment effect
We intended to use the following measures of the effect of treat-
ment:
• For time-to-event data, we intended to use the HR.
• For dichotomous outcomes, we planned to analyse data
based on the number of events and the number of participants
assessed in the intervention and comparison groups. We planned
to use these to calculate the RR and 95% confidence interval
(CI).
• For continuous outcomes, we planned to analyse data based
on the mean, SD and number of participants assessed for both
the intervention and comparison groups to calculate MD
between treatment arms with a 95% CI. If the MD was reported
without individual group data, we intended to use this to report
the study results. If more than one study measured the same
outcome using different tools, we planned to calculate the
standardised mean difference (SMD) and 95% CI using the
inverse variance method in RevMan 5 (RevMan 2014).
It was not possible to undertake these calculations as most studies
only had a treatment group and no control, and for the one study
with a comparator insufficient details were given.
Unit of analysis issues
We used participants as the unit of analysis. In the case of repeated
measurements, we recorded data at one month, three months and
six months.
Dealing with missing data
We contacted study authors to obtain missing data (participant,
outcome or summary data). For participant data, we conducted
evidence synthesis on an intention-to-treat basis. We reported on
the levels of loss to follow-up and assessed this as a source of
potential bias.
For missing outcome or summary data, we have not imputedmiss-
ing data and we have reported any assumptions in the review.
Assessment of heterogeneity
The studies included participants with a range of primary cancers
so there was substantial clinical heterogeneity between included
studies therefore meta-analysis and a statistical assessment of het-
erogeneity were not possible. If studies had been similar enough
based on consideration of primary cancer to allow pooling of data
8Home parenteral nutrition for people with inoperable malignant bowel obstruction (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
using meta-analysis, we planned to assess the degree of heterogene-
ity by:
• visual inspection of forest plots;
• estimation of the percentage heterogeneity (I² statistic)
between trials which cannot be ascribed to sampling variation
(Higgins 2003);
• formal statistical test of the significance of the heterogeneity
(Chi² test) (Deeks 2001).
We intended to regard heterogeneity to be substantial if the I²
statistic value was greater than 30% and either the T² value was
greater than zero, or there was a low P value (< 0.10) in the Chi²
test for heterogeneity.
Given the heterogeneity of the data, we used a narrative approach
to synthesise the data.
Assessment of reporting biases
It was not possible to explore publication bias using a funnel plot
(Higgins 2011).
Data synthesis
Quantitative synthesis
We intended to perform a meta-analysis using the fixed-effect
model in RevMan 5 (RevMan 2014) if a sufficient number of
clinically similar studies (in terms of primary cancer diagnosis)
were available to ensure meaningful conclusions, and if statistical
heterogeneity was low (I² statistic < 30%). If there was variability
in the primary cancer diagnosis of included studies, or if statisti-
cal heterogeneity was substantial (I² statistic > 30%), we planned
to use the random-effects model with inverse variance for meta-
analysis (DerSimonian 1986). We planned to only include non-
randomised studies with two or more comparison groups if statis-
tical adjustments were made for baseline imbalances.
• For time-to-event data, we planned to pool HRs using the
generic inverse variance facility in RevMan 5 (RevMan 2014).
• For any dichotomous outcomes, we intended to calculate
the RR for each study and we would then have pooled these.
• For continuous outcomes, we planned to pool the MD
between the treatment arms at the end of follow-up, if all trials
measured the outcome on the same scale; otherwise we intended
to pool standard mean difference (SMD) values.
However, we were unable to pool the data statistically using meta-
analysis, therefore we conducted a narrative synthesis of the results.
Qualitative synthesis
It was not possible for us to undertake a meta-synthesis as no
qualitative studies were identified.
Subgroup analysis and investigation of heterogeneity
We reported on different lengths of survival of participants with
different types of cancer where these data were available.
Sensitivity analysis
Insufficient numbers of studies met the review inclusion criteria
to undertake a sensitivity analysis to determine if the findings were
altered by excluding trials of high risk of bias as determined by the
Cochrane ’Risk of bias’ tool (Higgins 2011).
We did not find any qualitative studies, therefore assessingwhether
any one article was adding disproportionately to the findings was
not required.
’Summary of findings’ table
To interpret the findings and to rate the certainty of the evi-
dence, two review authors (AMS and JS) used the GRADE ap-
proach (Guyatt 2011) and the guidelines provided inChapter 12.2
of the Cochrane Handbook for Systematic Reviews of Interventions
(Schünemann 2011). First, we analysed the overall certainty of ev-
idence for each outcome individually, downgrading the evidence
from ’low’ as all the studies were observational to ’very low’ de-
pending on the risk of bias, indirectness of evidence, inconsistency,
imprecision of effect estimates or potential publication bias. After-
wards, we took this into account to draft the review conclusions.
We used theGRADEproGDT software to produce a ’Summary of
findings’ table with the results of this analysis (GRADEpro 2015).
We considered the following outcomes.
• Survival.
• Quality of life measured on a validated questionnaire.
• Adverse events of central venous catheter infection or
hospitalisation due to PN.
Meta-analysis was not possible, so we have presented results in a
narrative ‘Summary of findings’ table format, such as that used by
Chan 2011 (Summary of findings for the main comparison).
R E S U L T S
Description of studies
Results of the search
Combining the references and removing the duplicates produced
a list of 3114 references.We conducted further electronic searches
on BNI, CINAHL, Web of Science, NHS Economic Evaluation,
Health Technology Assessment, ClinicalTrials.gov and the World
Health Organization (WHO) International Clinical Trials Reg-
istry Platform. This uncovered a further 2120, which was reduced
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to 1876 once duplicates were removed. The resulting 4990 refer-
ences were screened for relevance by two review authors. The fol-
lowing authors screened studies: AMS, JS, CT, AC and SL. This
identified 146 references that were potentially eligible for inclu-
sion in the review. Two review authors( AMS and JS) excluded 111
studies as notmeeting the inclusion criteria on full-text review; one
study which should have completed could not be found in full text
and we had no response from the contact author,further details
can be found in Characteristics of ongoing studies. We excluded a
further 24 studies following discussion with a third review author
(SB). Two additional references were found; one from using the
similar articles feature on Pubmed and one from screening the
reference lists of other studies. A total of 13 studies with a total of
721 participants were included in the review.
For further details, please see the PRISMA diagram Figure 1
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Figure 1. Study flow diagram.
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Included studies
See Characteristics of included studies
Design
We included 13 studies in the review. Six studies were conducted
prospectively (Bozzetti 2002; Chermesh 2011; Cotogni 2017;
Finocchiaro 2002;Mercadante 1995; Pironi 1997), and seven ret-
rospectively (Abu-Rustum 1997; August 1991; Duerksen 2004;
Keane 2018; King 1993; Santarpia 2006; Soo 2008). From the
prospective studies two were cohort (Chermesh 2011; Cotogni
2017) and four were case series (Bozzetti 2002; Finocchiaro 2002;
Mercadante 1995; Pironi 1997) and from the retrospective studies,
six were case series (August 1991; Duerksen 2004; Keane 2018;
King 1993; Santarpia 2006; Soo 2008), and one was a cohort
study (Abu-Rustum 1997). We contacted the authors of three in-
cluded studies for more information on patient characteristics and
received no further data from them ( Abu-Rustum 1997; Bozzetti
2002; Pironi 1997).
Setting
Three included studies were conducted in the USA (Abu-Rustum
1997; August 1991; King 1993), six in Italy (Bozzetti 2002;
Cotogni 2017; Finocchiaro 2002;Mercadante 1995; Pironi 1997;
Santarpia 2006), one in Israel (Chermesh 2011), one in Canada
(Soo 2008), and one in England (Keane 2018). All the participants
had parenteral nutrition (PN) at home. One study included par-
ticipants who had PN in hospital and at home (Duerksen 2004),
however, data were only extracted for participants at home.
Participants
Therewere 721participants considered in this review ofwhich 308
were male and 384 female. We were unable to extract the gender
for 29 participants. There was a wide age range; some studies gave
age as median which varied between 54 to 62 years (range 32 to 79
years) and others as mean 48.76 (SD 13.8) to 60 (SD 28) years.
There was a wide variety of cancer diagnoses in participants: 237
gynaecological (including ovarian, endometrial, cervical and peri-
toneal), 390 gastro-intestinal (oesophagus, stomach, pancreas, col-
orectal and appendix), 14 lung,11 breast, five haematological, four
kidney, three head-neck, and 57 from other sites.
Some of the participants received oncology treatment whilst on
PN; 174 had chemotherapy, 20 had radiotherapy and 14 had
surgery, with some participants receiving more than one treatment
(Abu-Rustum 1997; Bozzetti 2002; Cotogni 2017; King 1993;
Soo 2008). Five studies gave no details about whether participants
were receiving any treatment (August 1991; Chermesh 2011;
Mercadante 1995; Pironi 1997; Santarpia 2006). In one study,
chemotherapy was given to some participants, but it is unclear
whether this pertained to the participants included in this review
(Duerksen 2004), and in two other studies the numbers receiving
chemotherapy whilst on PN were unclear (Finocchiaro 2002;
Keane 2018).
In most of the studies, there was no information about the oral
intake of the participants (August 1991; Bozzetti 2002; Chermesh
2011;Duerksen2004;Keane2018;King 1993;Mercadante 1995;
Pironi 1997; Santarpia 2006; Soo 2008). Finocchiaro 2002 re-
ported that 32 participants (46%) were taking oral nutrition,
but gave no information as to calorie intake, and similarly.
Abu-Rustum 1997 commented that participants were taking a liq-
uid diet, but gave no information on oral energy intake. Cotogni
2017 reported participants taking a median of 500 kcal per day.
Baseline performance status was measured and reported in nine
studies using Karnofsky performance status, where a higher
score indicates better performance (Bozzetti 2002; Cotogni 2017;
Duerksen 2004; Finocchiaro 2002; Keane 2018; King 1993;
Pironi 1997; Santarpia 2006; Soo 2008). Four studies reported
median Karnofsky performance status, which was 60 to 70
(range 40 to 90) (Bozzetti 2002; Cotogni 2017; Duerksen 2004;
Finocchiaro 2002). Keane 2018 and Soo 2008 reported mean
Karnofsky performance status as 50 ± 16 and 62.7 (SD 18.52),
respectively. King 1993 reported Karnofsky performance status as
48, but it was unclear if this was mean or median and no range or
standard deviation *SD) was given. Pironi 1997 found Karnofsky
performance status was 30 to 40 in 9 (31%) participants, 50 to
60 in 18 (62%) participants and 70 to 80 in 2 (7%) participants.
Santarpia 2006 reported Karnofsky performance status as≤ 40 in
12 participants and ≥ 50 in 52 participants. No measure of per-
formance status was reported in four studies (Abu-Rustum 1997;
August 1991; Mercadante 1995; Chermesh 2011)
No studies reported on confounding factors such as use of steroids,
whichmay improve the symptoms ofmalignant bowel obstruction
(MBO); neither did any studies comment on co-morbidities in
participants.
Interventions
The intervention we considered was home parenteral nutrition
(HPN) and all of the participants identified in included studies
received PN at home. However, six of the studies gave no details
about the nutritional composition of administrated solutions (
Abu-Rustum 1997; Chermesh 2011; Cotogni 2017; Duerksen
2004; King 1993; Pironi 1997), whereas this information was
available in the other studies.
In August 1991, solutions contained 1.0 L to 3.0 L of crystalline
amino acid (4.25% or 5.0%), dextrose (25% to 35%), and ap-
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propriate electrolytes, vitamins and minerals. Most participants
received lipid emulsion (250 mL of a 20% solution) weekly. Par-
ticipants had individually-tailored regimens, although no details
were given. In Bozzetti 2002, the aim was 30 non-protein kcal/kg/
day for participants. The median values for the PN preparations
were 300 g/day glucose (range 160 g to 500 g), 60 g/day lipid
(range 42 g to 100 g) and 12 g/day nitrogen (range 6.2 g to 13.7
g). Finocchiaro 2002 aimed to match energy intake with nutri-
tional guidelines for the Italian population multiplied by a specific
illness factor (Società Italiana Nutrizione Umana 1996), 1.2 g/kg/
day protein and 30 mL to 35 mL/kg/day fluid. Initially, partici-
pants were given 1500 mL/day (750 mL to 2500 mL), 1400 kcal/
day (600 kcal to 1900 kcal), 60 g/day (30 g to 85 g) of protein and
added micronutrients, which gave them 27.8 mL/kg (13.3 mL to
52.6 mL) and 24.4 kcal/kg (8.5 kcal to 40 kcal). In Mercadante
1995, solutions contained 1500 kcal to 2000 kcal, composed of
dextrose (providing 60% to 70% of energy) and 10% fat emul-
sion (approximately 30% to 40% energy), essential amino acids
enriched with branched-chain L-amino acids (approximately 17
g to 20 g), and electrolytes and vitamins as required. Keane 2018
gave mean requirements for PN, which were volume 2251 mL ±
626 mL, 11 ± 3 g/day nitrogen, 911 ± 304 kcal/day glucose, 573
± 262 kcal/day lipid, 112 ± mmol/day sodium, 57 ± 26 mmol/day
potassium, 5 ± 2mmol/day calcium, 10 ± 5mmol/daymagnesium
and 21 ±10 mmol/day phosphate. Santarpia 2006 did not com-
ment on solution composition, but aimed for individualised nu-
tritional support providing 20 to 30 kcal/kg/day, 3 to 4 g/kg/day
carbohydrate, 1 g/kg/day lipid and 1.0 to 1.5 g/kg/ day protein.
Similarly, Soo 2008 did not comment on solution composition,
but aimed for 25 kcal/kg, 1 g/kg protein and standard provision
of micronutrients for participants.
Comparators
Ten studies were case series that lacked comparator arms (August
1991; Bozzetti 2002; Duerksen 2004; Finocchiaro 2002; Keane
2018; King 1993;Mercadante 1995; Pironi 1997; Santarpia 2006;
Soo 2008). One study (Abu-Rustum 1997) compared chemo-
therapy and PN with chemotherapy alone and another (Cotogni
2017) compared PN and treatment (chemotherapy, radiotherapy
or a combination of both) with PN alone. One study had a com-
parator that was not relevant for this review (Chermesh 2011),
which compared PN inMBO with benign disease. However, data
were only extracted for the MBO participants.
Outcome
Survival
All of the studies reported the overall survival of participants on
PN. However, the definition of survival was inconsistent between
the studies, and at times unclear. Some defined survival from the
start of HPN (Bozzetti 2002; King 1993; Santarpia 2006), which
could be assumed to be from discharge, until death. Other stud-
ies explicitly stated that survival was measured from discharge
until death (August 1991; Chermesh 2011; Keane 2018); whilst
others were unclear, but it has been assumed by the review au-
thors that the survival interval was calculated from discharge until
death (Cotogni 2017; Finocchiaro 2002; Pironi 1997; Soo 2008).
Abu-Rustum 1997 measured survival from venting gastrostomy
placement. In Mercadante 1995 and Duerksen 2004, survival was
measured from initiation of PN. Therefore, in these three stud-
ies (Abu-Rustum 1997; Duerksen 2004; Mercadante 1995), sur-
vival was calculated over a longer time period as the measurement
started whilst the patient was in hospital.
Quality of life
Four of the studies described quality of life of participants receiv-
ing HPN (Bozzetti 2002; Cotogni 2017; Finocchiaro 2002; King
1993). Three of the studies used a validated instrument tomeasure
quality of life (Bozzetti 2002; Cotogni 2017; Finocchiaro 2002):
Bozzetti 2002 used theRotterdamSymptomChecklist, which par-
ticipants filled in monthly, and presented detailed results from 64
participants after one month on PN; lower scores represent better
quality of life. Cotogni 2017 used participant-completed Euro-
pean Organization for Research and Treatment of Cancer Quality
of Life Questionnaire Core 30 Version 3.0 (EORTC QLQ-C30).
Scores ranged between zero and 100 with higher scores indicating
better quality of life in the domains: global quality of life, physical
functioning, role functioning, emotional functioning, cognitive
functioning and social functioning. In the domains: appetite loss,
fatigue, nausea and vomiting and financial impact, lower scores
indicate a better quality of life. Participants completed the ques-
tionnaire before initiation of HPN in the presence of a healthcare
professional and subsequently at home, monthly for four months.
Finocchiaro 2002 used the Therapy Impact Questionnaire with
27 participants treated for more than two months, although it was
unclear who completed the questionnaire; lower scores indicated
a better quality of life. King 1993 employed various criteria to
assess quality of life. Physical and psychological well-being were
assessed by Karnofsky Performance Status, level of activity, morale
and presence of pain, fatigue, gastrointestinal discomfort, nausea,
vomiting and diarrhoea; apart from Karnofsky Performance Sta-
tus, criteria were measured by a one (usual or best) to five (worse
or never) scale. Social interactions with friends and family were
also measured on the same one-to-five scale. King 1993 also re-
ported participant employment or recreational travel as present or
absent. It was unclear in the King 1993 study who was assessing
participant quality of life, but they gathered the information from
medical records, interviews with participants and family, and from
healthcare professionals.
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Measurement of gastrointestinal symptoms
Most studies did not monitor gastrointestinal symptoms. How-
ever in some studies gastrointestinal symptoms were measured in
combination with other symptoms and could not be abstracted
separately (Bozzetti 2002; Cotogni 2017). King 1993 investigated
gastrointestinal discomfort, nausea and vomiting and diarrhoea
using a scale of one (usual or best) to five (worst or never) prior
to PN and at one-month intervals. Finocchiaro 2002 presented
symptoms of nausea and vomiting in 27 participants treated for
longer than two months on HPN; these were measured as part of
the Therapy Impact Questionnaire where a lower score indicates
a better outcome.
Measurement of nutritional status
Four studies (Bozzetti 2002; Finocchiaro 2002; King 1993;
Santarpia 2006) measured nutritional status. Bozzetti 2002 mon-
itored nutritional status at the start of treatment until death; mea-
suringweight, serumalbumin, lymphocyte count and serum trans-
ferrin. Finocchiaro 2002 reported on nutritional status before PN
and after two months in the 27 (of 70 participants) who survived
longer than two months. They measured weight and patient-gen-
erated-subjective global assessment (PG-SGA); PG-SGA is mea-
sured as either A, B or C with A representing the best nutritional
status and C the worst. King 1993 measured nutritional status
prior to HPN and at one week, one month, three months, six
months and one year; as per protocol we report on measures at
baseline, one month, three months and six months. King 1993
measured weight, serum albumin and serum transferrin. Santarpia
2006 reported weight at baseline and one month in two tables for
participants who lived more than 60 or 90 days. We report the
data for 64 participants surviving for 60 or more days.
Qualitative reports of symptoms
No studies had qualitative reports of symptoms.
Adverse events
Nine studies gave information on adverse events (August 1991;
Chermesh 2011; Cotogni 2017; Duerksen 2004; Finocchiaro
2002; King 1993; Mercadante 1995; Pironi 1997; Soo 2008).
They included information about a variety of major and minor
adverse events that participants encountered, but as per protocol,
we report only on central venous catheter infection and hospital-
isations due to PN complications.
Health economic outcomes
Two of the studies considered cost (Mercadante 1995; Pironi
1997). However, they did not consider cost in a health economic
evaluation such as quality adjusted life years.
Excluded studies
See Excluded studies
We provide details of 24 excluded studies. We listed studies as
excluded if they were obtained in full text and were discussed by
three review authors: AMS, JS and SB. The summary of reasons
for exclusion included the following.
• The study did not address the aim of the review (Bozzetti
2015; Chen 2013; Diver 2013; Villares 2001; Villares 2004).
• Patients did not received HPN (Brard 2006; Chakraborty
2011; Chouhan 2016; Fan 2007; Oh 2014; Szefel 2016; Tunca
1981).
• The number of people with MBO was not specified or was
lower than 70% (Bozzetti 2014; Girke 2016; Hoda 2005;
Mercadante 2015; Tang 1995; Vashi 2014).
• Only hydration was received by patients (Gemlo 1986;
Mercadante 1995a).
• Data were included in another study (Pasanisi 2001;Gupta
2015).
• Review article (Naghibi 2015).
• Unable to extract data from patients who received home
parenteral nutrition Guerra 2015.
Risk of bias in included studies
All the studies were case series or cohort studies; participants were
not randomised to treatments, there was no group allocation con-
cealment and no blinding of participants, personnel or assessors.
Therefore, the risk of bias in all studies was high.
Allocation
Allocation bias was high in all studies. Participants were not ran-
domised to treatments and there was no group allocation conceal-
ment. In most of the studies there was only one treatment group
and no comparator (August 1991; Bozzetti 2002; Duerksen 2004;
Finocchiaro 2002; Keane 2018; King 1993; Mercadante 1995;
Pironi 1997; Santarpia 2006; Soo 2008). Three studies had two
groups (Abu-Rustum 1997; Chermesh 2011; Cotogni 2017); al-
though Chermesh 2011 compared participants with MBO and
those with benign disease and onlyMBOparticipants are included
in this review. The decision for which treatments a participant
received seems to have been clinically driven as no information is
given about group allocation.
Blinding
Performance and detection bias for all studies is high as there was
no blinding of participants, healthcare professionals or assessors
to treatment received.
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Incomplete outcome data
Attrition bias across most of the studies was low as all participants
were accounted for in the outcomesmeasured (Abu-Rustum 1997;
August 1991; Bozzetti 2002; Chermesh 2011; Duerksen 2004;
Keane 2018; Mercadante 1995; Pironi 1997; Santarpia 2006; Soo
2008). In four studies there was a high attrition rate in the mea-
surement of quality of life or nutritional status due to patient death
(Cotogni 2017; Finocchiaro 2002; King 1993; Santarpia 2006).
In Cotogni 2017, quality of life was measured at four months in
less than half the participants. Finocchiaro 2002 only measured
quality of life and nutritional status in 27 of 70 participants who
had PN for longer than four months. In King 1993, there was a
high attrition rate in measurement of nutritional status with only
18 out of 61 participants measured at three months. Santarpia
2006 measured nutritional status at one month in those surviving
more than 60 days in 64 of 152 participants.
Selective reporting
It was unclear if selective reporting was present as we were unable
to locate protocols for the studies.
Other potential sources of bias
There did not appear to be any other sources of bias present.
The risk of bias in the included studies is summarised in Figure 2
and displayed graphically in Figure 3
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Effects of interventions
See: Summary of findings for the main comparison Parenteral
nutrition (PN) for inoperable malignant bowel obstruction
(MBO)
Primary outcomes
Survival
Survival was measured in all of the studies; see Figure 4. Seven
of the studies (August 1991; Chermesh 2011; Cotogni 2017;
Duerksen 2004; Keane 2018; Mercadante 1995; Santarpia 2006)
gave survival at different time points, as can be seen in Table 1.
However, we are uncertain whether HPN improves survival in
MBO patients as the evidence was very low certainty.
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Figure 4. Mean survival and standard deviations calculated from median and range (Hozo 2005) for all
studies apart from Keane 2018; Pironi 1997; Soo 2008 which presented mean survival
In six of the studies, all of the participants hadMBO (Abu-Rustum
1997;August 1991;Chermesh2011;Duerksen 2004;Mercadante
1995; Santarpia 2006). The median survival of participants across
the studies was 15 days to 155 days with a range of three days to
1278 days.
However, in sevenof the studies the percentage of participantswith
MBO ranged from 70% to 89% (Bozzetti 2002; Cotogni 2017;
Finocchiaro 2002; Keane 2018; King 1993; Pironi 1997; Soo
2008); the other participants in the group were given PN for other
reasons such as poor oral intake. The median survivals intervals
were two to four months with a range of 0.07 to 26months. Keane
2018, Pironi 1997 and Soo 2008 calculated survival as arithmetic
means rather than medians and found a mean survival of 12 (SD
8) weeks and five months (range 0.25 to 33), respectively. Keane
2018 reported both median survival, 14 weeks (interquartile range
(IQR) 5 to 34), and mean survival 31 weeks (95% CI 21 to 40).
Finocchiaro 2002 did not report mean or median survival, but at
the end of the 14-month study period 41 out of 70 participants
had died.
There were no patients lost to follow up from any of the studies.
In five studies (Abu-Rustum 1997; August 1991; Duerksen 2004;
Mercadante 1995; Santarpia 2006), all patients had died by the
end of the study period. Five studies clearly stated the number of
patients alive at the end of the study (Chermesh 2011; Cotogni
2017; King 1993; Pironi 1997; Soo 2008); the numbers alive
ranged from one to 13 patients, which was between 3% to 12%
of the study populations. In Bozzetti 2002; Finocchiaro 2002 and
Keane 2018, it was unclear how many patients were still alive at
the end of the study period as all had patients censored from the
analysis; for example if patients resumed oral intake or refused
HPN.
In addition to investigating overall survival, Abu-Rustum 1997
investigated survival in participants treated with chemotherapy
and PN and participants treated with chemotherapy alone; me-
dian survival was 89 days and 71 days, respectively. In contrast,
Cotogni 2017 measured survival in 72 participants receiving PN
and treatment (chemotherapy, radiotherapy or both) and in 39
participants receiving only PN; after three months, 54 (75%) par-
ticipants with treatment survived compared to 20 (51%) partici-
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pants with no treatment; after six months, 10 (26%) participants
with no treatment survived compared to 28 (39%) participants
having treatment.
Two of the studies described survival statistics according to the dif-
ferent primary cancer diagnoses (August 1991; Duerksen 2004);
see Table 2. Ovarian cancer had the shortest median survival and
gastric cancer had the longest.
Quality of life
Quality of life was measured by four studies (measured in 268
participants) (Bozzetti 2002; Cotogni 2017; Finocchiaro 2002;
King 1993). We are uncertain whether HPN improves quality of
life in MBO patients as the evidence was very low certainty. The
studies using a validated measure (Bozzetti 2002; Cotogni 2017;
Finocchiaro 2002) presented amixedpicture.Cotogni 2017 found
an improvement over three months for global quality of life. Two
studies (Bozzetti 2002; Finocchiaro 2002), reported around half
of participants showed no change, a quarter to a fifth deteriorated
and a quarter to a third improved.
More information about quality of life for the three studies with
validated measures (Bozzetti 2002; Cotogni 2017; Finocchiaro
2002) is given in Table 3
Secondary outcomes
Measurement of gastrointestinal symptoms
Two studies (measured in 88 participants) (Finocchiaro 2002;
King 1993) measured gastrointestinal symptoms and found some
participants symptoms improved, others deteriorated and some
had no change; see Table 4. We are uncertain whether HPN im-
proves gastrointestinal symptoms inMBOpatients as the evidence
was very low certainty.
Measurement of nutritional status
Four studies (measured in 221 participants) (Bozzetti 2002;
Finocchiaro 2002; King 1993; Santarpia 2006), measured nutri-
tional status and found that it was maintained. However, we are
uncertain of the impact of HPN on nutritional status as the evi-
dence was very low certainty.
More information about nutritional status is given in Table 5
Qualitative reports of symptoms
No studies contained qualitative descriptions of symptoms.
Adverse events
Nine studies (371 participants) gave information on adverse events
(August 1991; Chermesh 2011; Cotogni 2017; Duerksen 2004;
Finocchiaro 2002; King 1993; Mercadante 1995; Pironi 1997;
Soo 2008); see Table 6 for more details. Eight studies (August
1991; Chermesh 2011; Duerksen 2004; Finocchiaro 2002; King
1993; Mercadante 1995; Pironi 1997; Soo 2008) reported the
number of participants with adverse events and 32 of 280 partici-
pants had a central venous catheter infection or were hospitalised
for PN complications, which equated to between 6% and 21%
of participants across the studies. Cotogni 2017 reported compli-
cations in the standardised way and found 0.33 catheter-related
bloodstream infections per 1000 catheter days. However, this re-
porting differed from the other studies and it is unclear howmany
participants this relates to. Although not specified in all studies,
it was assumed that any patients with central venous catheter in-
fections were hospitalised. The Common Terminology Criteria
for Adverse Events considers any hospitalisation as a grade three
or severe complication (US Department of Health and Human
Services, 2017).
The other studies did not report adverse events. It was not clear
whether this was because participants did not suffer from any or
they were not reported.
Health economic outcomes
Two studies (42 participants) considered cost (Mercadante 1995;
Pironi 1997). Mercadante 1995 considered the cost of providing
PN solution, which in 1995 was $80 daily. However, this figure
does not include pharmacist time or other healthcare costs. Pironi
1997 found that in from 1 July 1995 to 30 June 1996, the cost
of the nutrition support team was approximately 14.2 European
CurrencyUnits for each patient per day and61EuropeanCurrency
Units for solutions, lines and dressing kits.
For an overview of the findings, see Summary of findings for the
main comparison.
D I S C U S S I O N
Summary of main results
This review included 721 participants from 13 studies (Abu-
Rustum 1997; August 1991; Bozzetti 2002; Chermesh 2011;
Cotogni 2017; Duerksen 2004; Finocchiaro 2002; Keane 2018;
King 1993; Mercadante 1995; Pironi 1997; Santarpia 2006; Soo
2008). No randomised controlled trials were identified and 10
studies had a single arm without a comparator group (August
1991; Bozzetti 2002; Duerksen 2004; Finocchiaro 2002; Keane
2018; King 1993;Mercadante 1995; Pironi 1997; Santarpia 2006;
Soo 2008). However, conducting randomised controlled trials in
this area is ethically difficult as patients who are not eating would
be allocated to being fed on a random basis.
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Survival
We are very uncertain about the impact of parenteral nutrition
(PN on survival of patients with malignant bowel obstruction
(MBO) as the certainty of the evidence was very low. Survival was
reported in all of the studies and 636 or 88% of participants were
dead at the end of the study and included in the survival analysis (
Abu-Rustum 1997; August 1991; Bozzetti 2002; Chermesh 2011;
Cotogni 2017; Duerksen 2004; Finocchiaro 2002; Keane 2018;
King 1993; Mercadante 1995; Pironi 1997; Santarpia 2006; Soo
2008). There was a wide variation of survival intervals reported in
the studies, with median survival periods of 15 to 155 days (range
three to 1278 days) and mean survival intervals of 85 to 164 days
(range eight to 1004 days). Unfortunately, due to heterogeneity
of cancer diagnosis and the differing start points for measuring
survival it was not possible to combine the study results. Although,
the hospital discharge date was most often used as the start point
for measuring survival, this is relatively arbitrary and influenced
by many non-disease-related factors making comparisons across
hospitals and different health systems difficult.
Quality of life
We are very uncertain about the impact of PN on quality of life of
patients with MBO as the certainty of the evidence was very low.
Results for quality of life were equivocal. Three studies used vali-
dated questionnaires (Bozzetti 2002; Cotogni 2017; Finocchiaro
2002). Cotogni 2017 found an improvement over three months
for global quality of life. Bozzetti 2002 and Finocchiaro 2002 had
a mixed picture showing both improvements for some patients
and deterioration for others
Adverse events
We are very uncertain about the impact of PN on adverse events
of patients with MBO as the certainty of the evidence was very
low. Adverse events were reported in nine studies (August 1991;
Chermesh 2011; Cotogni 2017; Duerksen 2004; Finocchiaro
2002; King 1993; Mercadante 1995; Pironi 1997; Soo 2008).
For eight studies, data for individual participants could be ex-
tracted, and 32 of 260 (12%) participants developed a central
venous catheter infection or were hospitalised for PN complica-
tions (August 1991; Chermesh 2011;Duerksen 2004; Finocchiaro
2002; King 1993; Mercadante 1995; Pironi 1997; Soo 2008).
Overall completeness and applicability of
evidence
The applicability and generalisability of the evidence for parenteral
nutrition in MBO is limited due to lack of adequate and compar-
ative data across the studies.
All of the studies reported survival data in some way, but there
were flaws in the estimates in terms of start point.
Quality of life was only measured in four studies and sequential
measurements were limited due to participant mortality.
Adverse events were only reported in nine of the 13 studies. It was
unclear whether no adverse events occurred in the other studies or
whether they were just not reported.
Quality of the evidence
Overall, the certainty of evidence was very low, derived mainly
from observational studies without a comparator.
Potential biases in the review process
The main bias is that evidence comes from case series and cohort
studies. There was no randomisation to treatment groups and no
blinding of participants or healthcare professionals. The measure-
ment of survival in 10 of the included studies was unclear or flawed
in that a process measure (discharge date) was used to define the
start point for measuring survival (August 1991; Bozzetti 2002;
Chermesh 2011; Cotogni 2017; Finocchiaro 2002; Keane 2018;
King 1993; Pironi 1997; Santarpia 2006; Soo 2008).
Agreements and disagreements with other
studies or reviews
Naghibi 2015 conducted a systematic review of people with MBO
having PN. They included 12 studies where more than 80% of
the participants had MBO. the study authors reported a survival
time of 83 days (median) and 116 days (mean). Unlike Naghibi
2015, we did not perform a meta-analysis of the survival time
due to the variety of cancer diagnoses, differing definitions of
survival time and flawed definition of survival period. However,
there was a rangemedian survivals across the studies 15 to 155 days
(range three to 1278 days), which is comparable to that reported
by Naghibi 2015 (median survivals were 15 to 140 days with a
range of three to 1004 days). Similar to our findings,Naghibi 2015
found limited data on quality of life and suggested that further
research into quality of life in these participants is required.
Naghibi 2015 also conducted base-case economic modelling for
HPN in palliative malignancy and found an incremental cost-
effectiveness ratio of £176, 587 per quality adjusted life year.None
of the studies in this review conducted quality adjusted life year
cost analysis of HPN.
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Implications for practice
Due to the very low certainty of evidence, we are very uncertain
whether parenteral nutrition (PN) improves length and quality of
life in people with malignant bowel obstruction (MBO).
Implications for research
The certainty of evidence in this review is very low and well-de-
signed prospective research is required. This is an area where it
is considered ethically difficult to conduct randomised controlled
trials, as noted above. However, it might be possible to randomise
people with very short estimated survival intervals to simple in-
travenous fluid support (e.g. saline) or parenteral nutrition (PN).
The majority of studies in this review were based on data from one
centre and there was heterogeneity in the cancer diagnosis, and
across the studies, in definitions of outcome measures. In order to
gather sufficient data to answer the question regarding the impact
of PN on survival and quality of life inMBO, prospective national
or international cohort studies are required with centres working
to the same protocol. Although, historically practice in the UK
and other countries (e.g. Denmark) has differed from the practice
in some countries such as USA and Italy in terms of percentage of
patients receiving PN with advanced cancer, the UK has seen an
increase use of PN in cases with advanced cancer (Brandt 2017;
Dibb 2017). Moreover, working from the same protocol would
mitigate against differences across countries. To give a robust mea-
sure, survival could be measured from the time PN commences in
addition to the time of discharge home. Investigation of quality of
life would benefit from qualitative studies using robust methods,
and quantitatively, the use of validated patient-reported outcome
measures and validated quality of life questionnaires (Aaronson
1993; Wilburn 2017). It may be useful to investigate change in
quality of life relative to baseline over the whole time period on
PN, as it could produce an initial improvement which falls with
advancing disease. In addition to investigating survival, there is a
need to be able to assess prognosis in people withMBO. It could be
argued that PN is adds little to patient survival if they succumb to
their disease within two weeks of starting the treatment. However,
most people could not survive without nutrition for more than 12
weeks and PN would seem beneficial in this instance. Currently,
guidelines for the use of HPN are based on predicting survival
(Bozzetti 2009). There is an urgent need to develop assessment
tools to estimate prognosis in these patients to enable HPN to be
offered to patients who are likely to live beyond the time required
to organise home parenteral nutrition (HPN).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Abu-Rustum 1997
Methods Design: retrospective cohort study
Aim: to determine the efficacy of intravenous chemotherapy alone orwith PN in restoring
bowel function
Country: USA
Funding: not reported
Participants Number: 21
Inclusion criteria: patients with advanced epithelial ovarian cancer, small bowel obstruc-
tion and salvage chemotherapy treated atMemorial Sloan-KetteringCancer Center 1990
to 1995
Exclusion criteria: not reported
Age: mean 54.5 years (range 32 to 75)
Gender: female
Cancer site: advanced ovarian cancer
• 16 (76%) IIIC
• 3 (14%) IV
• 1 (5%) IIB
• 1 (5%) not defined
Patients in MBO: 100%
Performance status: not reported
Treatment received: salvage intravenous chemotherapy
• 8 paclitaxel
• 7 platinum-based regimen
• 6 third line single agent or combination chemotherapy (doxorubicin, ifosfamide,
fluorouracil, mitoxantrone or mitomycin C
Interventions Chemotherapy alone or in combination with PN. Details of PN solutions or nutritional
aims were not reported
Outcomes • Length of survival with or without chemotherapy: from venting gastrostomy
placement
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No randomisation
Allocation concealment (selection bias) High risk No concealment of group allocation
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Abu-Rustum 1997 (Continued)
Criteria for assignment to treatments Unclear risk Insufficient information to permit judge-
ment
Comparability of treatment groups Unclear risk No details given about the two groups
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Length of survival: no missing outcome
data
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Other bias Low risk The study appears to be free of other
sources of bias
August 1991
Methods Design: retrospective case series
Aim: to review the Yale-New Haven Hospital experience with HPN in MBO patients
to determine the efficacy, safety, and indications for HPN in this patient population
Country: USA
Funding: not reported
Participants Number 17
Inclusion criteria: patients discharged from Yale-New Haven Hospital 1980 to 1989
with MBO and receiving HPN
Exclusion criteria: not reported
Age: median 58 years (range 33 to 79)
Gender: 13 female and 4 male
Cancer site: (n)
• Ovarian (9)
• Colon (4)
• Endometrium (1)
• Appendix (2)
• Stomach (1)
Patients in MBO: 100%
Performance status: not reported
Treatment received: not reported
Interventions HPN regimen individually designed to meet protein, calorie and fluid requirement, and
avoid metabolic complications
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August 1991 (Continued)
HPN solution: 1.0 to 3.0 L crystalline amino acid (4.25% or 5.0%), dextrose (25% to
35%) with appropriate electrolytes, vitamins and minerals. Most patients received lipid
emulsion (250 mL of 20% solution) weekly
Outcomes • Length of survival: from date of discharge to HPN
• Adverse events: readmissions from review of medical notes
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No randomisation
Allocation concealment (selection bias) High risk No group allocation concealment
Criteria for assignment to treatments Unclear risk Insufficient information to permit judge-
ment
Comparability of treatment groups Unclear risk Only one treatment group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No Blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No Blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk • Length of survival: no missing
outcome data
• Quality of life: no missing outcome
data
• Adverse events related to HPN
reported in one patient and it is presumed
no other adverse events occurred
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Other bias Low risk The study appears to be free of other
sources of bias
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Bozzetti 2002
Methods Design: prospective case series
Aim: to investigate changes in the quality of life in cancer patients during HPN and to
determine whether it is possible to predict length of survival before administering HPN
Country: Italy
Funding: not reported
Participants Number: 69
Inclusion criteria: advanced cancer patients enrolled in HPN programme from six Italian
cancer centres over three years
Exclusion criteria: not reported
Age: mean 54 years
Gender: 28 female and 41 male
Cancer site: (n)
• Colorectal (21)
• Stomach (16)
• Uterus/ovary (13)
• Breast (2)
• Other (17)
Patients in MBO: 84%
Performance status: Karnofsky performance status median 60 (40 to 90)
Treatment received: 36 patients had second- or third-line chemotherapy
Interventions HPN regimen designed to give 30 non-protein kcal/kg/day.
HPN solution: Median glucose 300 g/day (160 g to 500g), median lipid 60 g/day (42
g to 100 g) and median nitrogen 12 g/day (6.2 g to 13.7g)
Outcomes • Length of survival: measured from date of first administration of HPN
• Nutritional status: measured by weight, serum albumin, lymphocyte count and
serum transferrin
• Quality of life: Rotterdam symptom checklist (RSCL)
• Gastrointestinal symptoms: as part of RSCL
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No randomisation
Allocation concealment (selection bias) High risk No group allocation concealment
Criteria for assignment to treatments Unclear risk Insufficient information to permit judge-
ment
Comparability of treatment groups Unclear risk Only one treatment group
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Bozzetti 2002 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk • Length of survival: no missing data
• Nutritional status: unclear, but
presume all participants included
• Quality of life: 5 participants did not
complete RSCL
• Gastrointestinal symptoms: 5
participants did not complete RSCL
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Other bias Low risk The study appears to be free of other
sources of bias
Chermesh 2011
Methods Design: prospective cohort study (two arms)
Aim: to define the role of PN in patients with MBO.
A group of MBO patients receiving HPN were compared to patients with HPN for
other reasons; only the MBO patients are included in the review
Country: Israel
Funding: not reported
Participants Number: 28
Inclusion criteria: patients 18 years or older receiving HPN discharged from Rambam
Healthcare campus January 2003 to July 2009
Exclusion criteria: not reported
Age: Mean 59.9 ± 12.7 years
Gender: 13 female and 15 male
Cancer site: (n)
• Ovary (9)
• Stomach (8)
• Colon (4)
• Pancreas (3)
• Breast (2)
• Squamous cell carcinoma of the larynx presumed (1)
• Carcinoid presumed (1)
Patients in MBO: 100%
Performance status: not reported
Treatment received: not reported
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Chermesh 2011 (Continued)
Interventions HPN given to all participants. No information was given about nutritional support aims
or composition of PN solutions
Outcomes • Length of survival: unclear how it was measured.
• Adverse events: unclear how this was measured
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No randomisation
Allocation concealment (selection bias) High risk No group allocation concealment
Criteria for assignment to treatments Unclear risk Insufficient information to permit judge-
ment
Comparability of treatment groups Unclear risk Only one treatment group was considered
in the review
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk • Length of survival: no missing data
• Adverse events: related to HPN
reported in eight participants and it is
presumed no other adverse events
occurred
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Other bias Low risk The study appears to be free of other
sources of bias
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Cotogni 2017
Methods Design: prospective cohort study (two arms)
Aim: to analyse the quality of life in advanced cancer patients onHPN, and to investigate
whether the combination with oncologic treatments correlates with changes in quality
of life
Patients on HPN receiving treatment (chemotherapy and/or radiation therapy) com-
pared to HPN patients without treatment
Country: Italy
Funding: not reported
Participants Number: 111
Inclusion criteria
• Proven and prolonged failure to meet nutrition requirement by oral or enteral
route
• Impending risk of death due to malnutrition
• Life expectancy >2 months
• Karnofsky performance status (KPS) >50
• Control of pain
• Absence of severe organ dysfunctions
• Written informed consent confirming that the patient accepted this modality of
nutrition support
Exclusion criteria: not reported
Age: Median 62 years (range 32 to 79)
Gender: 54 female and 57 male
Cancer site: (n)
• Stomach (38)
• Colon/rectum (21)
• Pancreas/biliary system (20)
• Oesophagus (10)
• Lung (10)
• Ovary (2)
• Others (10)
Patient in MBO: 80%
Performance status: Karnofsky performance status, median 70 (range 60 to 80)
Treatment received: chemotherapy 61, radiation therapy 2 and both treatments 9
Interventions HPN given to all participants. No information was given about nutritional support aims
or composition of PN solutions
Outcomes • Length of survival: unclear how it was measured
• Quality of life: European Organisation for Research and Treatment of Cancer
Quality of Life Questionnaire Core 30. It was completed in outpatients in the presence
of a healthcare professional, and then at home monthly for four months
• Adverse events: unclear how this was measured
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Cotogni 2017 (Continued)
Random sequence generation (selection
bias)
High risk No randomisation
Allocation concealment (selection bias) High risk No group allocation concealment
Criteria for assignment to treatments Low risk Detailed criteria given, although there was
only one treatment group
Comparability of treatment groups Unclear risk Only one treatment group was considered
in the review
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk • Length of survival: no missing data
• Quality of life: all participants
accounted for but high attrition rate due
to death 49/111 completed at four
months
• Adverse events: incidence of
catheter-related bloodstream infections
reported and it is presumed no other
adverse events occurred
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Other bias Low risk The study appears to be free of other
sources of bias
Duerksen 2004
Methods Design: retrospective case series
Aim: to determine whether a subgroup of participants with intestinal obstruction would
benefit from support with PN
Patients receiving PN at home and in hospital included in study, only HPN patients
included in this review
Country: Canada
Funding: not reported
Participants Number: 5
Inclusion criteria
• No evidence of end-organ failure
• An obstructed GI tract
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Duerksen 2004 (Continued)
• An estimated life expectancy longer than 2 to 3 months
Exclusion criteria: not reported
Age: mean 44.6 years (37 to 57)
Gender: 2 female and 3 male
Cancer site: (n)
• Colon (3)
• Gastric (2)
Patient in MBO: 100%
Performance status: median Karnofsky performance status 60 (50 to 70)
Treatment received: chemotherapy 3
Interventions HPN given to all participants. No information was given about nutritional support aims
or composition of PN solutions
Outcomes • Length of survival: unclear how it was measured
• Adverse events: unclear how this was measured
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No randomisation
Allocation concealment (selection bias) High risk No group allocation concealment
Criteria for assignment to treatments Unclear risk Insufficient information to permit judge-
ment
Comparability of treatment groups Unclear risk Only one treatment group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk • Length of survival: no missing data
• Adverse events: no missing data
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Other bias Low risk The study appears to be free of other
sources of bias
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Finocchiaro 2002
Methods Design: Prospective case series
Aim: To assess HPN requirements, quality of life and complications in advanced cancer
patients
Country: Italy
Funding: Not reported
Participants Number: 70
Inclusion criteria
• Being included in the ASL home-care program
• Being unable to feed themselves or being unable to use enteral feeding to reach
the daily nutritional requirements (absent oral feeding, or insufficient with daily
nutritional requirement < 75%)
• Life expectancy > 30 days
• Controlled or absent pain
• No severe functional damage to vital organs
• Clinical and environmental conditions sustainable with home-care therapy
• Informed consent from the patient and/or a relative to practice the PN
• Positive feedback from the Therapeutic Unit
Exclusion criteria: not reported
Age: Mean 60 years (±28)
Gender: 37 female, 33 male
Cancer site: (n)
• Stomach (16)
• Pancreas/biliary system (15)
• Colorectal (14)
• Ovary (9)
• Lungs (3)
• Uterus( 3)
• Gut lymphoma (3)
• Kidneys (2)
• Other (5)
Patients in MBO: 70%
Performance status: Karnofsky index, median 60 (range 40 to 80)
Treatment received: palliative oncologic therapy 12 (17%)
Interventions HPN regimen designed to give energy requirements for the Italian population multiplied
by specific ill factor 1.3 (Società Italiana Nutrizione Umana 1996); energy was 60%
carbohydrate and 40% fat, 1.2 g/kg/day protein, 30 mL to 35 mL/kg/day fluid and
micronutrients
HPN solution: Initially 1500 mL/day (750 mL to 2500 mL), energy intake 1400 Kcal/
day and 60 g/day protein
Outcomes • Length of survival: unclear how it was measured
• Quality of life: therapy impact questionnaire for quality of life
• Nutritional status: weight, patient generated subjective global assessment
• Adverse events: metabolic (hyperglycaemia and electrolyte imbalance), clinical
(nausea and vomiting) and venous catheter (infections, thrombosis and catheter
damage) complications were monitored. For each complication typology, duration,
treatment and outcome were recorded.
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Finocchiaro 2002 (Continued)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No randomisation
Allocation concealment (selection bias) High risk No group allocation concealment
Criteria for assignment to treatments Low risk Detailed criteria given, although there was
only one treatment group
Comparability of treatment groups Unclear risk Only one treatment group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk • Length of survival: no missing data
• Quality of life: only measured in 27
participants treated longer than two
months
• Nutritional status: only measured in
27 participants treated longer than two
months
• Adverse events: no missing data
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Other bias Low risk The study appears to be free of other
sources of bias
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Keane 2018
Methods Design: retrospective case series
Aim: to examine the prognostic significance of performance status, type and site of tu-
mour, previous or concurrent chemo-radiotherapy, anthropometric characteristics, nu-
tritional and inflammatory status, demographic characteristics, serum biochemistry, and
prognostic indices based on a large cohort of patients with advanced cancer receiving
HPN at University College London Hospitals
Country: England
Funding: none received
Participants Number: 107
Inclusion criteria
• Adult patients, ≥18 years
• Advanced cancer
• Discharged on HPN from University College London Hospitals
• January 1 2006 to October 15 2016
Exclusion criteria: lost to follow-up
Age: Mean age 57 ± 12 years
Gender: 68 females, 39 males
Cancer site: (n)
• Gynaecological (37)
• Upper Gastrointestinal (21)
• Lower Gastrointestinal (24)
• Hepato-pancreatobiliary (10)
• Haematological (5)
• Other (10)
Patients in MBO: 74.4%
Performance status: Karnofsky index Mean 50 ± 16.
Treatment received: 97 (90%) had chemotherapy before and/or during PN
Interventions HPN given to all participants. Mean requirements were volume 2251 mL ± 626 mL, 11
± 3 g/day nitrogen, 911 ± 304 kcal/day glucose, 573 ± 262 kcal/day lipid, 112 ± mmol/
day sodium, 57 ± 26 mmol/day potassium, 5 ± 2 mmol/day calcium, 10 ± 5 mmol/day
magnesium, 21 ±10 mmol/day phosphate
Outcomes • Length of survival: measured from discharge until death
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No randomisation
Allocation concealment (selection bias) High risk No group allocation concealment
Criteria for assignment to treatments Low risk Detailed criteria given, although there was
only one treatment group
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Keane 2018 (Continued)
Comparability of treatment groups Unclear risk Only one treatment group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Length of survival: no missing data
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Other bias Low risk The study appears to be free of other
sources of bias
King 1993
Methods Design: retrospective case series
Aim: to determine ifHPN improvedpatients’ nutritional parameters, survival andquality
of life
Country: USA
Funding: not reported
Participants Number: 61
Inclusion criteria: gynaecological cancer patients who received HPN during 1981 to
1990 and had records on the John L. McKelvey Tumor Registry or the CHAMP Home
Care Program at the University of Minnesota Hospital and clinics
Exclusion criteria: not reported
Age: mean 55 years
Gender: not reported
Cancer site:
• Ovarian 56%
• Cervix 25%
• Corpus 15%
• Vulva 3%
• Vagina 1%
Patients in MBO: 72%
Performance status: Karnofsky performance status 48
Treatment received:
• Surgery 23%
• Chemotherapy 51%
• Radiotherapy 12%
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King 1993 (Continued)
Interventions HPN given to all participants. No information was given about nutritional support aims
or composition of PN solutions
Outcomes • Length of survival: date of initiation of HPN until last follow-up
• Quality of life: physical and psychological well-being - level of activity, morale and
presence of pain, fatigue, GI discomfort, nausea, vomiting and diarrhoea one (usual or
best) to five (worse or never) scale, and Karnofsky Performance Status. Social
interactions with friends and family - one (usual or best) to five (worse or never) scale.
Patient employment or recreational travel - present or absent.
• Nutritional status: weight, serum albumin, serum transferrin measured at one
week, one month, three months, six months and one year
• Adverse events: unclear how this was measured
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No randomisation
Allocation concealment (selection bias) High risk No group allocation concealment
Criteria for assignment to treatments Unclear risk Insufficient information to permit judge-
ment
Comparability of treatment groups Unclear risk Only one treatment group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk • Length of survival: no missing data
• Quality of life: no missing data
• Nutritional status: high attrition due
to mortality
• Adverse events: related to HPN
reported in eight participants and it is
presumed no other adverse events
occurred
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
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King 1993 (Continued)
Other bias Low risk The study appears to be free of other
sources of bias
Mercadante 1995
Methods Design: prospective case series
Aim: to describe clinical experience with HPN patients
Country: Italy
Funding: not reported
Participants Number: 13
Inclusion criteria: advanced cancer patients receiving HPN at Pain Relief and Palliative
Care Unit over five years
Exclusion criteria: not reported
Age: mean 56 years (32 to 71)
Gender: 8 women and 5 men
Cancer site: (n)
• Pharynx (1)
• Colon (4)
• Stomach (1)
• Breast (1)
• Ileum (2)
• Ovary (2)
• Oesophagus (1)
• Pancreas (1)
Patients in MBO: 100%
Performance status: not reported
Treatment received: not reported
Interventions HPN given to all participants.
HPN solution: 1500 Kcal to 2000 Kcal, dextrose (approximately 60% to 70% of energy)
, 10% fat emulsion (approximately 30% to 40% energy), essential amino acids enriched
with branched chainL amino acids (approximately 17 g to 20 g), electrolytes and vitamins
as required
Outcomes • Length of survival: unclear how it was measured
• Adverse events: unclear how this was measured
• Health economic measure: cost of materials and nutrients per day
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No randomisation
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Mercadante 1995 (Continued)
Allocation concealment (selection bias) High risk No group allocation concealment
Criteria for assignment to treatments Unclear risk Insufficient information to permit judge-
ment
Comparability of treatment groups Unclear risk Only one treatment group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk • Length of survival: no missing data
• Adverse events: related to HPN
reported in one participant and it is
presumed no other adverse events
occurred
• Health economic: no missing data
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Other bias Low risk The study appears to be free of other
sources of bias
Pironi 1997
Methods Design: prospective case series
Aim: to estimate the utilisation rate of home artificial nutrition (HAN); evaluate the
efficacy of HAN in preventing death from cachexia, maintaining participants at home
without burdens and distress to patient and family and in improving participants’ per-
formance status; and obtain information about cost-determining items of HAN
Study reported on home enteral and PN patients; only HPN patients are included in
this review
Country: Italy
Funding: not reported
Participants Number: 29
Inclusion criteria
• Hypophagia - defined as oral calorie intake absent or < 50% of basal energy
expenditure
• Life expectancy > 6 weeks
• Suitable patient and family circumstances (pain absent or controlled, no severe
vital organ failure, emotional stability, willingness and ability to cope with home
artificial nutrition- related activities and suitable hygienic conditions
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Pironi 1997 (Continued)
• Verbal consent obtained
Exclusion criteria
• Absence of hypophagia
• Estimated life expectancy < 6 weeks
• Unsuitable home/family conditions
• Lack of consent
Age: not possible to distinguish between enteral and PN group
Gender: not possible to distinguish between enteral and PN group
Cancer site: n (%)
• Head-neck 3 (10%)
• Gastrointestinal 18 (63%)
• Lung 1 (3%)
• Genitourinary 4 (14%)
• Others 3 (10%)
Patients in MBO: 89%
Performance status: Karnofsky performance status n (%)
30 to 40 in 9 (31%)
50 to 60 in 18 (62%)
70 to 80 in 2 (7%)
Treatment received: not reported
Interventions HPN given to all participants. No information was given about nutritional support aims
or composition of PN solutions
Outcomes • Length of survival: unclear how it was measured
• Adverse events: unclear how this was measured
• Health economics: cost of solutions, infusion line and dressing kits
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No randomisation
Allocation concealment (selection bias) High risk No group allocation concealment
Criteria for assignment to treatments Low risk Detailed criteria given, although there was
only one treatment group
Comparability of treatment groups Unclear risk Only one treatment group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding
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Pironi 1997 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk • Length of survival: no missing data
• Adverse events: related to HPN
reported in three participants and it is
presumed no other adverse events
occurred
• Health economic: no missing data
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Other bias Low risk The study appears to be free of other
sources of bias
Santarpia 2006
Methods Design: retrospective case series
Aim: to identify predictors of survival in participants with carcinomatosis on HPN
Country: Italy
Funding: not reported
Participants Number: 152
Inclusion criteria: patients consecutively referred for nutrition support to Naples Clinical
Nutritional Unit January 1996 to September 2003
Exclusion criteria: not stated
Age: mean 57.8 years (± 13.6)
Gender: 107 female and 45 male
Cancer site: (n)
• Stomach (48)
• Ovary (42)
• Colorectum (30)
• Endometrium (7)
• Breast (6)
• Ileum (5)
• Gallbladder (4)
• Pancreas (3)
• Kidney (2)
• Skin (1)
• Prostate (1)
• Abdominal sarcoma (1)
• Unknown (2)
Patients in MBO: 100%
Performance status: Karnofsky performance score in 64 participants
• score ≤ 40 in 12
• score ≤ 50 in 52
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Santarpia 2006 (Continued)
Treatment received: not stated
Interventions HPN regimen individualised to participant’s requirements containing 20 kcal/kg to 30
kcal/kg/day, 3 g to 4 g carbohydrate/kg/day, 1.0 g/kg/day lipid, 1.0 g to 1.5 g/kg/day
protein
HPN solution: all-in-one formula containing amino acids, glucose, lipids, minerals, trace
elements and vitamins
Outcomes • Length of survival: unclear how this was measured
• Nutritional status: weight and laboratory tests
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No randomisation
Allocation concealment (selection bias) High risk No group allocation concealment
Criteria for assignment to treatments Unclear risk Insufficient information to permit judge-
ment
Comparability of treatment groups Unclear risk Only one treatment group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk • Length of survival: no missing data
• Nutritional status: only measured in
64/152 participants surviving > 60 days
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Other bias Low risk The study appears to be free of other
sources of bias
44Home parenteral nutrition for people with inoperable malignant bowel obstruction (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Soo 2008
Methods Design: retrospective case series
Aim: to describe patient-related variables in a cohort of advanced cancer patients enrolled
in a HPN program
Country: Canada
Funding: not reported
Participants Number: 38
Inclusion criteria
• Clear cancer diagnosis
• Condition that would benefit from HPN
• Life expectancy in the order of months
Exclusion criteria
• Medically unstable
• Physically or cognitively impaired
• Home environment prohibiting proper treatment
• Able to tolerate enteral nutrition
Age: mean 48.76 years (± 13.8)
Gender: 27 female and 11 male
Cancer site: (n)
• Ovarian (13)
• Colon (6)
• Gastric (6)
• Peritoneal( )3
• Oesophageal (2)
• Carcinoid (1)
• Cervical (1)
• Ampullary (1)
• Gastrointestinal stromal tumours (1)
• Anaplastic large lymphoma (1)
• Rectal (1)
• Unknown (2)
Patients in MBO: 84%
Performance status: Karnofsky performance score mean 62.7 (± 18.53)
Treatment received: n (%)
• chemotherapy 14 (36.8%)
• chemotherapy + radiotherapy 2 (5.3%)
• no treatment 23 (60.5%)
Interventions HPN regimen individually designed by a registered dietitian to provide 25 kcal/kg, 1 g/
kg protein and standard provision of electrolytes, trace elements, vitamins and minerals
HPN solution: not reported
Outcomes • Length of survival: unclear how it was measured
• Adverse events: unclear how this was measured
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Soo 2008 (Continued)
Random sequence generation (selection
bias)
High risk No randomisation
Allocation concealment (selection bias) High risk No group allocation concealment
Criteria for assignment to treatments Unclear risk Insufficient information to permit judge-
ment
Comparability of treatment groups Unclear risk Only one treatment group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk • Length of survival: no missing data
• Adverse events: related to HPN
reported in five participants and it is
presumed no other adverse events
occurred
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Other bias Low risk The study appears to be free of other
sources of bias
GI: gastrointestinal; HAN: home artificial nutrition; HPN: home parenteral nutrition; MBN: malignant bowel obstruction; PN:
parenteral nutrition; RSCL: Rotterdam symptom checklist
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bozzetti 2014 MBO < 70%
Bozzetti 2015 Inappropriate aim for this review: Quote: “The purpose of developing and validating a nomogram to predict
survival ” Survival data for participants not presented
Brard 2006 Not specified that participants received PN at home
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(Continued)
Chakraborty 2011 Only one patient had PN at home
Chen 2013 Inappropriate setting for this review: Quote: “TPN in patients with advanced-stage, incurable cancer and
peritoneal carcinomatosis in a hospital setting”
Chouhan 2016 Not specified that participants received PN at home
Diver 2013 Inappropriate aim for this review: Quote: “The aim of the study is to review a single institution’s experience
with gastrostomy tubes”
Fan 2007 Not specified that participants received PN at home
Gemlo 1986 Received hydration and not complete nutrition
Girke 2016 Number in MBO not specified
Guerra 2015 Unable to extract data for those receiving TPN at home separately from those receiving it in hospital
Gupta 2015 Abstract for Chouhan 2016 data
Hoda 2005 Percentage of MBO <70%
Mercadante 1995a Some participants received hydration and not complete nutrition
Mercadante 2015 MBO < 70%
Naghibi 2015 Review paper
Oh 2014 Not specified that participants received PN at home
Pasanisi 2001 Data included in Santarpia 2006
Szefel 2016 Participants received TPN in hospital
Tang 1995 MBO < 70%
Tunca 1981 Participants received TPN in hospital
Vashi 2014 Not specified that participants had MBO
Villares 2001 No outcomes relevant for review
Villares 2004 No outcomes relevant for review
MBN: malignant bowel obstruction; PN: parenteral nutrition
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Characteristics of ongoing studies [ordered by study ID]
Dreesen 2012
Trial name or title Prospective non-interventional non-controlled multicenter observational study to evaluate the quality of care
for adult patients on HPN
Methods Prospective observational study
Participants Inclusion criteria:
• patients in Flanders who speak Dutch;
• older than 18 years;
• able to give an informed consent.
Exclusion criteria:
• patients who are younger than 18 years.
Interventions Aim: to give an overview of a number of aspects related to the quality of care for adult patients on HPN
Outcomes Primary outcomes:
• quality of life (time frame: 2 years) with the HPN-QoL or FACIT-G.
• number of catheter-related infections (time frame: 2 years)
Starting date May 2012
Contact information Mira Dreesen, PhD student, PhD Student, Katholieke Universiteit Leuven, mira.dreesen@uzleuven.be
Notes Emailed contact author and no response
HPN: home parenteral nutrition; QoL: quality of life
A D D I T I O N A L T A B L E S
Table 1. Length of Survival
Study Numbers in study N surviving 1month N surviving > 1-3
months
N surviving > 3-6
months
N surviving ≥ 6
months
August 1991 17 14 12 5 1
Chermesh 2011 68 23 14 4 3
Cotogni 2017 111 - 74a 38 24b
Duerksen 2004 5 4 4 2 2
Keane 2018 107 - 53a 19 19
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Table 1. Length of Survival (Continued)
Mercadante 1995 13 3 3 2 0
Santarpia 2006 152 96 62 37 37
N=Numbers
aSurvival was measured from 0 to 3 months in these studies.
bNumber surviving at 9 months
Table 2. Survival for different cancer diagnoses
Study Survival - median (range) in days
Ovarian cancer n = 9 Endometrial cancer
n = 1
Gastrointestinal can-
cer n = 3
Colon cancer Gastric cancer n = 2
August 1991 39 (10 to 77) 51 159 (106 to 208) 89 (5 to 168)a
Duerksen 2004 155 (72 to 433)b 258 (84 to 431)
a n = 4
b n = 3
Table 3. Quality of life
Study Numbers of participants Timepoint Quality of lIfe measure Score
Bozzetti 2002 69a Baseline Rotterdam Symptom Checklist Well-being assessment (n)c
Very well 3
Well 55
Not well 38
Ill 0
Missing 4
64 1 Month Rotterdam Symptom Checklist Well-being assessment change from
baseline (n)
Increased 15
No change 32
Decreased 17
Cotogni 2017 111a Baseline EORTCb Mean (SD) Global QoLd 52 (17)
97 1 Month EORTC Mean (SD) Global QoL 58 (17)
76 2 Months EORTC Mean (SD) Global QoL 66 (17)
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Table 3. Quality of life (Continued)
54 3 Months EORTC Mean (SD) Global QoL 71 (14)
Finocchiaro 2002 70a Baseline Therapy impact questionnaire Values not given
27 2 Months Therapy impact questionnaire Change from baseline
Deterioration 20.5%
Stationary 48%
Improving 31.5%
aTotal number in the study
bEORTC = European Organization for Research and Treatment of Cancer Quality of life Questionnaire Core 30
c Number
dQuality of life
Table 4. Gastrointestinal symptoms
Study Numbers in
study
Numbers
gastroin-
testinal
symptoms
measured
Time point Measure Nauseaa Vomiting Gastroin-
testinal dis-
comfort
Diarrhoea
King 1993 61 61 Baseline Unvalidated
b
3.2 - 2.8 2.0
61 During
HPN
- 2.7 - 2.4 1.8
Finocchiaro
2002
71 27 Baseline Therapy im-
pact ques-
tionnaire
Values not
given
Values not
given
- -
27 2 months Therapy im-
pact ques-
tionnaire
Change
from Base-
line
Deteriora-
tion 26%
Stationary
42%
Improving
32%
Change
from Base-
line
Deteriora-
tion 15%
Stationary
57%
Improving
28%
- -
aNausea and vomiting measured together
b 1 to 5 scale where 1 is usual or best and 5 is worse or never
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Table 5. Nutritional status
Study Numbers
nutritional
status mea-
sured
Timepoint Weight
(kg)
Albumin
(g/dl)
Transferin
(mg/dL)
Lympho-
cytes
(x 109/L)
Choles-
terol (mg/
dL)
Haemo-
globin (g/
dL)
PG-SGA
score (%)
Bozzetti
2002
69 Baseline Median
52.5 (35.5
to 77.5)
Median 3.
3 (2.2 to 4.
8)
Median
189 (26 to
420)
Median 1.
15 (0.15 to
3.05)
- - -
69 Before
death
Median
54.0 (36 to
78)
Median 3.
2 (2.2 to 4.
7
Median
180 (65 to
414)
Median 1.
2
(0.24 to 3.
65)
- - -
Finoc-
chiaro
2002
27a (of 70) Baseline 51 (37 to
76)
3.15 (1.2
to 4)
- - - - B - 33%
C - 67%
27 2 months 52.2 (40 to
71)
3.14 (1.7
to 4.5)
- - - - A - 15%
B - 37%
C - 48%
King 1993 61 Baseline Mean 54.5
(13.7)
Mean 2.5
(0.6)
Mean 149
(48)
- - - -
50 1 month Mean 57.2
(12.4)
Mean 2.4
(0.6)
Mean 149
(60.2)
- - - -
18 3 months Mean 57.7
(11.2)
Mean 2.9
(0.6)
Mean 195
(62.2)
- - - -
9 6 months Mean 59.8
(11.7)
Mean 3.1
(0.7)
Mean 225.
4 (77)
- - - -
Santarpia
2006
64a (of
152)
Baseline Mean 51.7
(10.3)
Mean 3.3
(0.6)
- Mean 1.48
(0.72)
Mean 154
(46)
Mean 11.0
(1.9)
-
64 1 month Mean 53.2
(10.3)
Mean 3.4
(0.5)
- Mean 1.46
(0.67)
Mean 150
(38)
Mean 10.5
(1.9)
-
aBaseline values given for those patients who had nutritional status measured later.
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Table 6. Adverse events
Study Number of participants in study Number with adverse events Number of catheter-related bloodstream in-
fections per 1000 catheter days
August 1991 17 1
Chermesh 2011 28 6
Duerksen 2004 5 1
Finocchiaro 2002 70 7
King 1993 61 8
Pironi 1997 28a 3
Mercadante 1995 13 1
Soo 2008 38 5
Cotogni 2017 111 0.33
Total 371 32
aAdverse events only reported in 28 patients who died. The whole population was 29
A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1. Neoplasms/
2. (neoplasm* or tumor* or tumour* or cancer* or malignan* or carcinoma* or adenocarcinoma* or carcinosarcoma* or sarcoma*).mp.
3. 1 or 2
4. exp Intestinal Obstruction/
5. ((bowel* or intestin* or gastrointestin* or gastro-intestin* or colon* or colorect* or retrosigmoid*) adj3 (obstruct* or occlu* or fail*
or block* or adhes*)).mp.
6. 4 or 5
7. 3 and 6
8. exp Parenteral Nutrition/
9. (total parenteral nutrition* or TPN* or parenteral nutrition* or PN*).mp.
10. ((parenteral* or artificial* or tub* or catheter* or intraven* or IV* or subcutan* or bypas*) adj3 (nutri* or hydration* or feed* or
fed* or treatment* or manag* or method* or car* or support* or diet*)).mp.
11. (home adj3 parenteral*).mp.
12. 8 or 9 or 10 or 11
13. 7 and 12
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Key
mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary
concept word, rare disease supplementary concept word, unique identifier
pt=publication type
ab=abstract
ti=title
sh=subject heading
Appendix 2. Embase search strategy
1. Neoplasm/
2. (neoplasm* or tumor* or tumour* or cancer* or malignan* or carcinoma* or adenocarcinoma* or carcinosarcoma* or sarcoma*).mp.
3. 1 or 2
4. exp Intestine Obstruction/
5. ((bowel* or intestin* or gastrointestin* or gastro-intestin* or colon* or colorect* or retrosigmoid*) adj3 (obstruct* or occlu* or fail*
or block* or adhes*)).mp.
6. 4 or 5
7. 3 and 6
8. exp Parenteral Nutrition/
9. (total parenteral nutrition* or TPN* or parenteral nutrition* or PN*).mp.
10. ((parenteral* or artificial* or tub* or catheter* or intraven* or IV* or subcutan* or bypas*) adj3 (nutri* or hydration* or feed* or
fed* or treatment* or manag* or method* or car* or support* or diet*)).mp.
11. (home adj3 parenteral*).mp.
12. 8 or 9 or 10 or 11
13. 7 and 12
Key
mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary
concept word, rare disease supplementary concept word, unique identifier
pt=publication type
ab=abstract
ti=title
sh=subject heading
Appendix 3. CENTRAL search strategy
#1 MeSH descriptor: [Neoplasms] explode all trees
#2 (neoplasm* or tumor* or tumour* or cancer* or malignan* or carcinoma* or adenocarcinoma* or carcinosarcoma* or sarcoma*)
#3 #1 or #2
#4 MeSH descriptor: [Intestinal Obstruction] explode all trees
#5 ((bowel* or intestin* or gastrointestin* or gastro-intestin* or colon* or colorect* or retrosigmoid*) near/3 (obstruct* or occlu* or
fail* or block* or adhes*))
#6 #4 or #5
#7 #3 and #6
#8 MeSH descriptor: [Parenteral Nutrition] explode all trees
#9 (total parenteral nutrition* or TPN* or parenteral nutrition* or PN*)
#10 (parenteral* or artificial* or tub* or catheter* or intraven* or IV* or subcutan* or bypas*) near/3 (nutri* or hydration* or feed* or
fed* or treatment* or manag* or method* or car* or support* or diet*)
#11 home near/3 parenteral*
#12 #8 or #9 or #10 or #11
#13 #7 and #12
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C O N T R I B U T I O N S O F A U T H O R S
SB, SL, CT provided a methodological perspective.
SL, GJ, AC, AT, AMR provided a clinical perspective.
AMS, JS, AC, SL, CT screened references
AMS, JS, LH extracted data
AMS, SB, JS wrote the review.
AMS, SL, JS, AC, CT, GCJ, AT, AMR EJS, LH, SB interpretation of data and commented on the review.
SB, SL, CT, AC secured funding for the review.
D E C L A R A T I O N S O F I N T E R E S T
Anne Marie Sowerbutts: none known
Simon Lal: none known
Andrew Clamp: none known
Chris Todd: none known
Gordon Jayson: none known
Antje Teubner: none known
Anne Marie Raftery: none known
Eileen J Sutton: none known
Jana Sremanakova: none known
Sorrel Burden:none known
Lisa Hardy: none known
S O U R C E S O F S U P P O R T
Internal sources
• University of Manchester, UK.
• The Christie NHS Foundation Trust, UK.
• Salford Royal Foundation Trust, UK.
• University of Bristol, UK.
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External sources
• Marie Curie, UK.
Marie Curie Research Grants Scheme
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Wemade it explicit that single-arm studies were included and participants only receiving intravenous fluids and not PN were excluded.
We planned to conduct searches incorporating both qualitative and quantitative search terms. However, we conducted a generic search
for malignant bowel obstruction (MBO) and parenteral nutrition (PN) which would include qualitative and quantitative studies.
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